Bayer supports haemophilia fund
Bayer Healthcare, Biological Products Division (Bayer BP), has announced plans to donate 2.15m units of Kogenate FS (antihaemophilic factor [recombinant], formulated with sucrose) to the World Federation of Haemophilia (WFH). The drug will be distributed by WFH to support the treatment needs of haemophilia patients in 13 countries across Asia, the Middle East, Africa and Central and South America, providing clotting factor for patients awaiting surgical, dental, emergency or life-saving procedures.
Bayer BP has made multiple product donations to the WFH to assist people living with haemophilia in developing countries, including a single donation of more than 12.2m units of Kogenate FS in 2004. Such donations form part of an ongoing commitment to improve and increase the delivery of quality care for the 400,000 haemophilia patients around the world. The company additionally supports World Haemophilia Day and other WFH programs.